Pre-market hot trades in US stocks: Corvex pre-market down 15.61%; Hoth Therapeutics pre-market down 8.19%

Pre-market Hot Trades in US Stocks Corvex, down 15.61% in pre-market trading, has no significant news recently. The trading is active with clear capital flow, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. HOTH is down 8.19% in pre-market trading. Based on recent key news: On April 14, Hoth Therapeutics announced HT-VA CRADA data, showing significant effects of GDNF on liver fat metabolism, surpassing Semaglutide. This news drove the stock price up by 42.02%. Source: Benzinga On April 14, Hoth Therapeutics' stock price has fluctuated significantly over the past year, with a low of $0.48 and a high of $2.11. This information reflects the market's concern about the stock's volatility. Source: Nasdaq On April 14, Hoth Therapeutics plans to enter the MAFLD and obesity market through gene-level mechanisms, supporting its position as a pioneer in metabolic reprogramming methods. This strategic positioning may affect stock price trends. Source: Reuters The competition in the obesity market is intensifying, focusing on gene therapy. Top Gainers in Pre-market US Stocks Allied Gaming & Entertainment is up 103.57% in pre-market trading. Based on recent key news: On April 14, Allied Gaming & Entertainment announced a comprehensive solution and strategic development path with Knighted Pastures. This move resolved all pending issues between the two parties and closed previous legal disputes, significantly boosting the stock price. Source: Reuters On April 14, Allied successfully resolved all pending issues with Knighted, leading to the complete closure of legal proceedings. This news enhanced market confidence, further driving the stock price up. Source: Reuters On April 14, Allied released original content detailing the comprehensive solution with Knighted, consolidating market confidence in the company's future development. Source: GlobeNewswire The US stock market has recently seen increased volatility, requiring attention to risks. Immutep is up 55.65% in pre-market trading. Based on recent key news: On April 15, Immutep received FDA orphan drug designation for eftilagimod alfa for soft tissue sarcoma. This designation supports potential late-stage development, with trials achieving primary endpoints in 38 evaluable patients, with a median tumor transparency/fibrosis of 51.5%. This news significantly boosted the stock price. On April 13, Immutep executives Marc Voigt and Deanne Diem Miller submitted stockholding reports, showing substantial holdings of common stock This shareholding information may enhance market confidence in the company's management, further driving up the stock price. On April 15, Rosen Law Firm encouraged Immutep investors to inquire about the collective securities class action investigation. Although this news may bring legal risks, it has not had a significant negative impact on the stock price. The biotechnology sector has performed strongly recently, with noticeable capital inflows. Liminatus Pharma, up 46.55% in pre-market trading, has had no significant news recently. Trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation